May 1, 2026 • 29 mins
A simple blood test or a quick tablet game can reveal Alzheimer’s-related brain changes years before memory problems start, and that rewrites what prevention can look like. We walk through the new detection tools, what early treatments and trials are trying to do, and why ethics and access may decide whether this revolution helps everyone.
• the shift from late diagnosis to risk reduction and early treatment
• why symptom-based diagnosis misses the best intervention window
• how digital cognitive tests detect microhesitations and processing delays
• how blood biomarkers reveal brain pathology without PET scans or lumbar punctures
• why early detection matters only if action follows
• approved medicines that slow early stages and what trials test pre-symptom
• the heart disease prevention analogy for brain health
• the U.S. POINTER trial pillars: physical activity, nutrition, social and cognitive challenge, health coaching
• why structure and accountability turn habits into clinical intervention
• counseling challenges and the psychological burden of a pre-diagnosis
• screening guidelines, insurance coverage, and equitable access as the next bottleneck
Keep asking the big questions, keep challenging the old models, and most importantly, keep learning.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:00):
Imagine it is years, um, maybe even a full decade
before you ever forget a nameor, you know, misplace your
keys.
SPEAKER_01 (00:08):
Right.
Years before any of thosesubtle, kind of terrifying
moments of cognitive slip evencross your mind.
SPEAKER_00 (00:14):
Exactly.
You are, for all intents andpurposes, perfectly healthy.
Yeah.
I mean your memory is sharp, youare at the peak of your career,
and you're fully independent.
Yeah, just living your life.
But then you go into yourdoctor's office and a simple
blood test, or or perhaps adigital game you play on a
tablet in the waiting room.
SPEAKER_01 (00:31):
Like just tapping a screen while you wait.
SPEAKER_00 (00:33):
Yeah.
And that simple thing predictsthat you are already on the
biological path to Alzheimer'sdisease.
SPEAKER_01 (00:39):
Aaron Ross Powell I mean, it sounds like science
fiction, right?
But it is rapidly becoming ourclinical reality.
We are really sitting at theedge of a massive medical
frontier here.
SPEAKER_00 (00:49):
Welcome to the deep dive.
For you listening, whetheryou're, you know, prepping for a
healthcare meeting, trying tocatch up on the latest medical
trends, or you're just insanelycurious about human biology.
Our mission today is to get youfully up to speed on this
revolution.
SPEAKER_01 (01:02):
Aaron Powell Because it really is a revolution.
SPEAKER_00 (01:03):
Aaron Powell It is.
We are unpacking a fundamentalparadigm shift in how the
medical world approachesAlzheimer's disease.
I mean, we're talking about amonumental transition from a
reactive approach to a highlyproactive preventive one.
SPEAKER_01 (01:18):
Aaron Ross Powell What's fascinating here is the
sheer overwhelming scale of theissue we're dealing with.
We're pulling today from anincredibly comprehensive report
from March 2026, published inMedical News Today.
Right.
And it details the findings ofthe spring 2025 Alzheimer's
Association research roundtable.
That report points out that anestimated 32 million people
(01:41):
worldwide are currently livingwith Alzheimer's disease.
SPEAKER_00 (01:44):
32 million.
That is, I mean, that is thepopulation of a moderately sized
country.
SPEAKER_01 (01:48):
Exactly.
32 million.
And for decades, modern medicinehas essentially been fighting
this really complex, devastatingform of dementia with one arm
tied behind its back.
SPEAKER_00 (01:58):
Aaron Powell The global scale is staggering.
SPEAKER_01 (01:59):
Yeah.
SPEAKER_00 (02:00):
Because it's not just the 32 million lives.
Right.
SPEAKER_01 (02:03):
Not at all.
SPEAKER_00 (02:03):
It's the exponential number of caregivers and family
members whose lives arecompletely altered by it.
Trevor Burrus, Jr.
SPEAKER_01 (02:09):
The ripple effect is huge.
SPEAKER_00 (02:11):
Yeah.
So to understand it why thisshift from reaction to
prevention is such a massivedeal, we need to look at the
baseline of where we are comingfrom.
The spring 2025 Alzheimer'sAssociation research roundtable
wasn't just, you know, a casualsymposium.
SPEAKER_01 (02:25):
Right.
It was a major gathering.
Trevor Burrus, Jr.
SPEAKER_00 (02:27):
The report highlights that it brought
together leaders from academia,medical practice, the
pharmaceutical industry, andgovernment.
Trevor Burrus, Jr.
SPEAKER_01 (02:34):
You basically bring all those stakeholders into one
room when the entire foundationof a medical discipline needs to
be rebuilt.
SPEAKER_00 (02:40):
Exactly.
And the core shift theyoutlined, which was officially
published in Alzheimer's andDementia, translational research
and clinical interventions, ismoving from responding to
symptoms after they appear tofocusing intensely on risk
reduction and you know muchearlier treatment.
SPEAKER_01 (02:57):
Aaron Ross Powell Yeah.
Dr.
Suzanne E.
Schindler, she's the associateprofessor of neurology at
Washington University School ofMedicine in St.
Louis.
Okay.
She was the co-chair of thatroundtable session.
And she made an observation thattruly defines the historical
failure of our approach.
SPEAKER_00 (03:12):
Aaron Ross Powell What did she say?
SPEAKER_01 (03:13):
She pointed out that up until now, many patients with
Alzheimer's disease are onlydiagnosed after they have
already developed majorcognitive impairment and loss of
function.
SPEAKER_00 (03:22):
Okay, let's unpack this because major cognitive
impairment and loss of functionis incredibly sterile clinical
language.
SPEAKER_01 (03:29):
You know, it hides the reality.
SPEAKER_00 (03:31):
Right.
In the real world, for you oryour family, that means someone
is already struggling to managetheir daily finances, or they're
getting lost driving a familiarroute.
SPEAKER_01 (03:41):
Or they're failing to recognize a loved one.
SPEAKER_00 (03:43):
Which is just heartbreaking.
It means the biology has alreadywreaked havoc on the behavior.
SPEAKER_01 (03:48):
Dr.
Schindler really isolates thecore of why that late diagnosis
is so problematic.
She states that patients andtheir care partners are
typically receiving thisdiagnosis after the window when
interventions are most helpfuland patients can make truly
independent decisions.
Wow.
Yeah.
That last phrase is critical.
SPEAKER_00 (04:07):
Right.
The loss of independent decisionmaking.
SPEAKER_01 (04:09):
Exactly.
Because that fundamentallychanges the ethics and the
efficacy of medical care.
SPEAKER_00 (04:14):
That is heavy.
Because the loss of independentdecision making means the
disease has already taken thedriver's seat.
SPEAKER_01 (04:21):
It has.
SPEAKER_00 (04:22):
You might no longer have the cognitive capacity to
decide how you want your caremanaged, right?
Or or participate meaningfullyin planning your own financial
or medical future.
SPEAKER_01 (04:32):
Or even fully consent to participating in
clinical trials, which is a hugeissue.
SPEAKER_00 (04:38):
Wait, really?
The trials themselves areaffected.
SPEAKER_01 (04:41):
Oh, absolutely.
The clinical trials aspect is amassive hurdle in itself.
If a patient cannot consent, theburden falls to a proxy, like a
family member.
I see.
And that slows down research andadds layers of ethical
complexity.
We have historically been tryingto treat a disease at the exact
moment the patient loses theability to fight back.
SPEAKER_00 (05:01):
It sounds like we've historically been trying to
board up the windows after thehurricane has already torn the
roof off.
SPEAKER_01 (05:06):
That's exactly what it is.
SPEAKER_00 (05:07):
I mean, the storm has passed, the damage is
catastrophic, and we are showingup with plywood and nails
saying, All right, let's securethe house.
SPEAKER_01 (05:14):
Aaron Powell Right, a little too late.
SPEAKER_00 (05:15):
Aaron Ross Powell But with what we are seeing in
this report, it feels like we'refinally getting a weather radar.
We can see the storm forminghundreds of miles offshore.
Yes.
But I guess my question is, whyhas it taken so long to build
this radar?
Why have we been operating inthe dark for decades?
SPEAKER_01 (05:33):
Well, the primary hurdle has always been the
physical isolation of the brain.
SPEAKER_00 (05:37):
Okay.
SPEAKER_01 (05:38):
The biology of Alzheimer's involves the buildup
of specific proteins and thegradual destruction of neural
pathways.
Right.
But for decades, thosebiological changes were entirely
invisible to us in a livingpatient.
Aaron Ross Powell Wow.
SPEAKER_00 (05:51):
So we just couldn't see it happening.
SPEAKER_01 (05:52):
Aaron Ross Powell Right.
We simply did not have thetechnology to peer into a living
brain and detect the diseaseprocess before it manifested as
severe behavioral symptoms.
SPEAKER_00 (06:00):
Aaron Ross Powell So we had to rely entirely on
outward, late-stage behavioralcues to infer what was happening
biologically.
SPEAKER_01 (06:07):
Trevor Burrus Exactly.
We had to wait for the memoryloss to know the brain was under
attack.
SPEAKER_00 (06:11):
Aaron Ross Powell That's terrifying.
SPEAKER_01 (06:12):
Aaron Ross Powell It is.
And that's why Dr.
Schindler calls this atransformational time, precisely
because the invisible isbecoming visible.
SPEAKER_00 (06:19):
Aaron Ross Powell The window of intervention
hasn't just been nudged open, ithas been dramatically widened.
SPEAKER_01 (06:25):
Aaron Ross Powell Right.
We are shifting toward detectingand treating Alzheimer's before
that major cognitive impairmenthas occurred.
SPEAKER_00 (06:32):
Trevor Burrus Which is incredible.
And that transition frominvisible to visible brings us
perfectly to the new toolsmaking this weather radar
possible.
SPEAKER_01 (06:40):
Yes, the diagnostic toolkit.
SPEAKER_00 (06:42):
Because if you're going to track the biological
storm before it hits thebehavioral shore, we need highly
sophisticated equipment.
The source material lays out aspecific four-part diagnostic
toolkit for early stagedetection.
SPEAKER_01 (06:55):
Right.
It mentions biomarkers,specialized blood tests,
neuroimaging, and digitalcognitive assessment tools.
SPEAKER_00 (07:01):
So each of these represents a monumental leap
forward from the historicalstandard, right?
SPEAKER_01 (07:05):
Oh, huge.
Historically, a cognitiveassessment often involves simply
asking a patient to draw theface of a clock.
SPEAKER_00 (07:12):
Right, the clock drawing test.
SPEAKER_01 (07:13):
Yeah, or trying to get them to remember a sequence
of three words during an annualcheckup.
SPEAKER_00 (07:18):
Which seems so basic compared to what we have now.
I really want to zero in on twoof these new tools because the
underlying mechanisms arefascinating.
Digital cognitive assessmenttools and specialized blood
tests.
We read about computerizedcognitive assessments detecting
changes many years before majorimpairment.
How does a digital game spot adisease that, like a trained
(07:42):
neurologist talking to a patientin a room, might miss?
SPEAKER_01 (07:45):
Well, the difference lies in the sensitivity of
measurement.
SPEAKER_00 (07:49):
Okay.
SPEAKER_01 (07:49):
A traditional cognitive test is pretty binary.
You either remember the threewords or you don't.
SPEAKER_00 (07:54):
Right.
SPEAKER_01 (07:54):
But a sensitive digital cognitive assessment is
measuring microhesitations.
SPEAKER_00 (07:58):
Microhesitations.
SPEAKER_01 (07:59):
Yeah.
It is tracking incredibly subtleshifts in reaction time, pattern
recognition, and processingspeeds.
SPEAKER_00 (08:05):
Oh wow.
SPEAKER_01 (08:05):
It measures how your brain navigates complex,
multifaceted digital tasks downto the millisecond.
SPEAKER_00 (08:12):
The millisecond.
So it's way beyond humanperception.
SPEAKER_01 (08:14):
Exactly.
A human observer cannot catch a50-millisecond delay in
cognitive processing during anormal conversation, but an
algorithm can.
SPEAKER_00 (08:22):
That makes me think of a mechanic listening to a car
engine.
SPEAKER_01 (08:25):
Okay.
Yeah.
SPEAKER_00 (08:26):
You know, the check engine light hasn't come on yet,
and the car is still drivingdown the highway at 60 miles an
hour, just fine.
But the mechanic plugs in adiagnostic computer and it
detects a microscopic misfire inone cylinder.
SPEAKER_01 (08:38):
Right.
SPEAKER_00 (08:39):
The driver feels absolutely nothing, but the
machine knows the engine isstarting to fail.
SPEAKER_01 (08:44):
That is a highly accurate way to visualize it.
The digital assessment isfinding the absolute earliest
behavioral echoes of thebiological changes.
SPEAKER_00 (08:53):
That's incredible.
SPEAKER_01 (08:54):
And complementing that behavioral data are the
specialized blood tests.
SPEAKER_00 (08:58):
Let's talk about those.
SPEAKER_01 (09:00):
Dr.
Schindler explicitly confirmedthat these blood tests can
detect Alzheimer's-related brainchanges many years before the
cognitive impairment becomesapparent.
SPEAKER_00 (09:09):
Okay, stop there because we need to explain the
how of this.
SPEAKER_01 (09:12):
Sure.
SPEAKER_00 (09:13):
Because the brain is separated from the rest of the
body's bloodstream by the bloodbrain barrier, right?
Which acts like a biologicalfortress.
SPEAKER_01 (09:21):
Very true.
SPEAKER_00 (09:22):
So how on earth are we finding a brain disease in a
vial of blood drawn fromsomeone's arm?
SPEAKER_01 (09:27):
It's a great question.
The blood brain barrier ishighly selective, but it is not
entirely impermeable, especiallyover a lifetime.
SPEAKER_00 (09:35):
Okay.
SPEAKER_01 (09:36):
As the biological hallmarks of Alzheimer's begin
to develop as specific proteinsbegin to accumulate or misfold
in the brain, microscopic tracesof these proteins or the
biological byproducts of braincell stress inevitably cross
over into the peripheralbloodstream.
SPEAKER_00 (09:52):
Oh, I see.
SPEAKER_01 (09:53):
We call these biomarkers.
They are basically thebiological fingerprints of the
disease.
SPEAKER_00 (09:58):
So the disease leaves a trail, and the blood
test is like the magnifyingglass.
SPEAKER_01 (10:02):
Exactly.
Previously, the only way toaccurately detect these specific
biomarkers was through a highlyinvasive lumbar puncture to draw
cerebrospinal fluid.
Ouch.
Yeah.
Or through incredibly expensivespecialized neuroimaging like a
PEET scan.
SPEAKER_00 (10:18):
And you can't just give PET scans to everyone.
SPEAKER_01 (10:20):
Right.
Those are not screening toolsyou can deploy to the general
population.
They're too costly and complex.
SPEAKER_00 (10:25):
Makes sense.
SPEAKER_01 (10:26):
But the advancement of specialized blood tests means
we can now detect theseminuscule biomarker fingerprints
in a standard blood draw.
SPEAKER_00 (10:33):
Which you can get in a normal physical.
SPEAKER_01 (10:35):
Exactly.
SPEAKER_00 (10:35):
For you listening, especially if you actively avoid
medical information overload,here is the clear, undeniable
takeaway from this section ofour deep dive.
The timeline of Alzheimer'sdisease has been fundamentally
rewritten.
SPEAKER_01 (10:49):
Completely rewritten.
SPEAKER_00 (10:51):
The disease begins biologically long before it
begins behaviorally.
You can be biologically positivefor the early stages of
Alzheimer's while still beingbehaviorally perfect.
SPEAKER_01 (11:02):
Yes.
And separating the biology fromthe behavior is the exact wedge
that allows modern medicine tostep in.
Right.
Because if we can find thedisease early, if we can see the
biomarker fingerprints in ahealthy 50-year-old, the
immediate next question is whatdo we actually do with that
information?
SPEAKER_00 (11:20):
Right.
It's a great question.
Because if we have the weatherradar and we see the storm
coming a decade away, but wedon't have an evacuation plan or
way to disperse the clouds.
SPEAKER_01 (11:29):
Then we haven't helped the patient.
SPEAKER_00 (11:31):
Exactly.
We've just given them a decadeof severe anxiety.
SPEAKER_01 (11:33):
Which brings us to the pharmaceutical side of this
paradigm shift.
The report features insightsfrom Dr.
Christopher Weber.
SPEAKER_00 (11:40):
He's the director of global science initiatives at
the Alzheimer's Association,right?
SPEAKER_01 (11:44):
Yes, he is.
And he makes a point that servesas the foundation for this
entire proactive movement.
SPEAKER_00 (11:50):
What's his point?
SPEAKER_01 (11:50):
He says that early detection enables all proven
interventions to have theirabsolute greatest benefit.
SPEAKER_00 (11:56):
You want to put out the fire when it's just a spark
on the curtains, not when thewhole house is engulfed.
SPEAKER_01 (12:01):
Perfectly said.
And we actually have treatmentsto deploy at the spork stage
now.
SPEAKER_00 (12:06):
Wait, right now.
Today.
SPEAKER_01 (12:08):
Yes.
The article notes that medicinesdesigned to slow the early
stages of Alzheimer's havealready been approved in the
United States and in othercountries.
Wow.
SPEAKER_00 (12:16):
So we aren't just waiting on future miracles.
We have tools available today.
SPEAKER_01 (12:20):
We do.
But the report goes evenfurther, detailing ongoing
clinical trials that are pushingthe envelope to the absolute
edge of early intervention.
SPEAKER_00 (12:29):
Okay.
SPEAKER_01 (12:29):
It specifically highlights two major studies
Trailblazer Allstairs 3 andAHEAD 345.
SPEAKER_00 (12:36):
The patient criteria for these trials is what makes
them so revolutionary, isn't it?
SPEAKER_01 (12:40):
Oh, absolutely.
They are testing these new drugson people who show early
biological signs in the brain,those biomarkers we just talked
about, but who do not yet haveany memory issues.
SPEAKER_00 (12:52):
That is wild.
They are giving Alzheimer'smedication to people who have
perfect functioning memories.
SPEAKER_01 (12:58):
Yes.
SPEAKER_00 (12:58):
So what is the mechanism of action here?
What are these drugs actuallydoing inside a healthy seeming
brain?
SPEAKER_01 (13:04):
Aaron Ross Powell Well, while the report doesn't
dive into the deep molecularchemistry, the conceptual
mechanism is about clearing thebiological debris.
SPEAKER_00 (13:12):
Okay, clearing debris.
SPEAKER_01 (13:14):
Yeah.
If the blood tests show that theproblematic proteins associated
with Alzheimer's are justbeginning to accumulate in the
brain, these trials are testingwhether introducing a drug now
can clear those proteins.
SPEAKER_00 (13:25):
Before they do damage.
SPEAKER_01 (13:26):
Exactly.
Clear them or halt theiraccumulation before they cause
enough cellular damage totrigger memory loss.
SPEAKER_00 (13:32):
That is incredible.
SPEAKER_01 (13:33):
Dr.
Weber offers a brilliantcomparison that really
demystifies this whole approach.
He likens this new strategy tohow doctors treat heart disease.
SPEAKER_00 (13:42):
Oh, I like that.
Think about heart disease.
We don't wait for the patient tobe clutching their chest in the
emergency room, having amassive, irreversible myocardial
infarction.
SPEAKER_01 (13:53):
No, we don't.
SPEAKER_00 (13:54):
We test their cholesterol when they're 40
years old.
If their lipid biomarkers arehigh, we prescribe a statin.
SPEAKER_01 (14:00):
Right.
We treat the biological riskfactor, the high cholesterol,
decades before the catastrophicbehavioral event, the heart
attack.
SPEAKER_00 (14:07):
And Dr.
Weber is suggesting we arefinally applying this exact same
preventive, proactive model tothe brain.
SPEAKER_01 (14:14):
That's it exactly.
We find the biological riskfactor, the early signs of
Alzheimer's pathology via bloodtests or digital assessments,
and we treat it biologicallybefore the memory degrades.
SPEAKER_00 (14:25):
Here's where it gets really interesting, though.
We can talk about biomarkers,lipid panels, and trials like
Trailblazer all day, but Dr.
Weber grounds this in a deeplyhuman reality.
SPEAKER_01 (14:35):
He really does.
SPEAKER_00 (14:36):
He told Medical News today giving people more time
without memory and thinkingchanges.
That's something everybodywants.
SPEAKER_01 (14:42):
It is the ultimate metric of success.
Not just clearing proteins, butpreserving humanity.
SPEAKER_00 (14:47):
Yes.
Because it is so easy to getlost in the clinical data of a
medical report, you know.
But this isn't just about movingstatistical numbers on a chart.
SPEAKER_01 (14:56):
No, not at all.
SPEAKER_00 (14:57):
Buying time is everything.
It's about preserving a person'sidentity, it's about preserving
their relationships, theirability to drive to the grocery
store, their ability to live intheir own home.
SPEAKER_01 (15:07):
Independence.
SPEAKER_00 (15:08):
Exactly.
If a preventative drug can givea grandfather five more years of
knowing his grandchildren'snames, that is an immeasurable
victory for that family.
SPEAKER_01 (15:19):
It is the definition of a medical breakthrough.
SPEAKER_00 (15:22):
It really is.
SPEAKER_01 (15:22):
However, the report clearly outlines that
pharmaceutical interventions arenot the only tools we have.
In fact, relying solely on apill ignores the behavioral and
environmental side of theequation entirely.
SPEAKER_00 (15:33):
Right, because there's more to health than just
taking a pill.
SPEAKER_01 (15:36):
Furthermore, for a huge portion of the global
population, these advanced drugsmight not be an option.
SPEAKER_00 (15:41):
Why not?
SPEAKER_01 (15:42):
Well, due to costs, geographical access, or
compounding medical conditions,some people just can't take
them.
SPEAKER_00 (15:48):
So if these new drugs are only for people who
can afford them or tolerate theside effects, what happens to
the millions of people who get apositive blood test but can't
take the pill?
SPEAKER_01 (15:59):
That's a huge concern.
SPEAKER_00 (16:01):
Because we can't just leave them hanging in the
reactive model, right?
Which brings us to the lifestylecomponent.
The Alzheimer's Associationisn't just focused on
pharmaceuticals, the round tableheavily emphasized early
lifestyle interventions.
SPEAKER_01 (16:15):
Yes.
And they specifically pointed tofindings from the U.S.
Pointer trial.
SPEAKER_00 (16:19):
Okay, tell me about the Pointer trial.
SPEAKER_01 (16:21):
Aaron Powell The U.S.
Pointer trial is fascinatingbecause it elevates lifestyle
modification from generic adviceto clinical intervention.
I see.
It identified four distinctpillars of intervention that
provided the most benefit forolder adults who were at high
risk of developing Alzheimer's.
SPEAKER_00 (16:37):
What are the four pillars?
SPEAKER_01 (16:38):
They are.
Physical activity, nutrition,social and cognitive challenges,
and health coaching.
SPEAKER_00 (16:44):
Okay.
I have to play the skeptic herefor a moment.
Go for it.
Because as a listener, you heareat right and exercise for
literally every disease underthe sun.
SPEAKER_01 (16:52):
It's sure it's a cliche at this point.
SPEAKER_00 (16:54):
Aaron Ross Powell It's the generic catch-all
advice for heart disease,diabetes, joint pain, bad sleep.
Are we really saying that eatinga side salad and doing a Sunday
crossword puzzle can actuallystop a biological juggernaut
like Alzheimer's disease?
SPEAKER_01 (17:09):
Oh man, if it were just a casual salad and a
crossword puzzle, you would beabsolutely right to be
skeptical.
Right.
But Dr.
Weber's specific phrasing in thereport is the key.
He states that research showshealthy habits with structure
and accountability can improvethinking and support brain
health.
SPEAKER_00 (17:26):
Okay.
Structure and accountability.
SPEAKER_01 (17:28):
There is a massive clinical difference between
occasionally deciding to take awalk versus a structured
medically accountableintervention program.
SPEAKER_00 (17:37):
Explain the difference.
How does structure actuallychange the outcome for the
brain?
SPEAKER_01 (17:40):
Let's break down the four pillars of the pointer
trial conceptually.
Physical activity isn't justmoving around, it's a targeted
cardiovascular regimen designedto increase blood flow and
oxygenate the brain, whichpotentially stimulates the
growth of new neuralconnections.
Nutrition isn't just eating lesssugar, it's a specific
prescribed overhaul designed toreduce systemic inflammation.
SPEAKER_00 (18:02):
And inflammation's a big deal.
SPEAKER_01 (18:04):
Massive.
We know systemic inflammation isa driver of neurodegenerative
disease.
SPEAKER_00 (18:08):
Got it.
What about the cognitive side?
SPEAKER_01 (18:11):
Social and cognitive challenges aren't passive games,
they are rigorous engagementsthat force the brain to process
unpredictable, real-timeinformation.
SPEAKER_00 (18:20):
Oh, like socializing.
SPEAKER_01 (18:22):
Yes.
Socializing requires readingfacial expressions, recalling
past conversations, andformulating responses.
SPEAKER_00 (18:29):
That's true.
SPEAKER_01 (18:29):
It is actually one of the most cognitively
demanding tasks a human canperform.
SPEAKER_00 (18:33):
That makes perfect sense.
Social interaction is areal-time stress test for the
brain's processing speed andmemory retrieval.
A crossword puzzle doesn't talkback or change the subject
unpredictably.
SPEAKER_01 (18:44):
Exactly.
And tying all of this togetheris the fourth pillar health
coaching.
SPEAKER_00 (18:49):
The accountability part.
SPEAKER_01 (18:50):
Right.
The coaching provides thestructure and accountability.
It ensures compliance, tracksprogress, and adjusts the
interventions based on thepatient's biological response.
Wow.
It is prescribed lifestylemodification, treated with the
exact same rigor and seriousnessas a pharmaceutical
prescription.
SPEAKER_00 (19:08):
It's the difference between doing some half-hearted
stretches in your living roomand going to a prescribed
redirected physical therapyprogram after a knee
replacement.
SPEAKER_01 (19:18):
Perfect analogy.
SPEAKER_00 (19:19):
The structure and the oversight are what drive the
physical adaptation.
SPEAKER_01 (19:23):
Dr.
Dung Trin, an internist andchief medical officer of the
Healthy Brain Clinic, providescrucial perspective on this in
the report.
SPEAKER_00 (19:30):
What does he say?
SPEAKER_01 (19:31):
He makes a statement that frames this entire
approach.
He says lifestyle changes shouldbe seen as foundational, not
optional.
SPEAKER_00 (19:38):
Foundational, not optional.
I love that.
SPEAKER_01 (19:40):
And he breaks down the utility of these structured
lifestyle measures into threedistinct practical roles in
clinical medicine.
SPEAKER_00 (19:47):
Let's walk through Dr.
Trin's three roles because thisis where the theory hits the
pavement.
SPEAKER_01 (19:52):
Okay, first, he points out that lifestyle
interventions are broadlyapplicable.
SPEAKER_00 (19:56):
Right.
SPEAKER_01 (19:56):
As we discussed, not everyone is going to be a
candidate for early stageAlzheimer's drugs, but almost
everyone, regardless of theirmedical background or financial
status, can safely engage insome form of structured physical
activity, nutritionalimprovement, and cognitive
challenge.
SPEAKER_00 (20:13):
Right.
It is an incredibly accessibletool.
You don't need a million-dollarlab to go for a vigorous walk or
have a deep conversation.
Exactly.
So if role one is accessibility,I imagine rule two is that it
stacks with the medication.
SPEAKER_01 (20:26):
You've hit the nail on the head.
SPEAKER_00 (20:27):
You aren't choosing between a pill and a diet,
you're attacking the diseasefrom multiple angles.
SPEAKER_01 (20:32):
Dr.
Trin notes that lifestylechanges complement medical
treatment.
They do not compete with it.
SPEAKER_00 (20:37):
That's great.
SPEAKER_01 (20:38):
If a patient is a candidate for the new
pharmaceuticals like those inthe trailblazer or a head
trials, adopting the fourpillars of the pointer trial
will only support that medicalintervention.
SPEAKER_00 (20:49):
You are clearing the biological debris with the drug
while simultaneously reducinginflammation and strengthening
neural pathways throughlifestyle.
SPEAKER_01 (20:59):
It is a comprehensive, two-pronged
attack.
SPEAKER_00 (21:02):
That makes total sense.
And the third role.
The third role is perhaps themost psychologically significant
for the patient.
SPEAKER_01 (21:08):
Okay.
SPEAKER_00 (21:09):
Dr.
Trin emphasizes that lifestylemeasures shift the conversation
from fear to empowerment.
SPEAKER_01 (21:16):
I want to highlight this for you listening because
this is the ultimatepsychological takeaway.
SPEAKER_00 (21:20):
It really is.
SPEAKER_01 (21:21):
Think about the historical Alzheimer's diagnosis
we talked about at thebeginning.
It was a death sentence for yourmemory, delivered when it was
too late to do anything,resulting in absolute fear and
helplessness.
But Dr.
Trent is pointing out thatbecause we can detect risk
earlier, patients can beginworking on their brain health
right away through thesestructured lifestyle changes.
SPEAKER_00 (21:42):
Yes, even while they are undergoing further medical
evaluation or are waiting fortrial approval.
SPEAKER_01 (21:48):
You don't have to sit in a waiting room paralyzed
by fear.
The power is back in your handsthe moment you leave the clinic.
It's a profound psychologicalshift.
But as we move from the clinicalideal of Empowerment to the
messy reality of the healthcaresystem, things get complicated.
Giving people this powerfulpredictive information years in
(22:08):
advance opens up an entirelynew, highly complex set of
problems.
SPEAKER_00 (22:14):
We absolutely have to address the fallout.
Up to this point, we've beenpainting a picture of total
scientific victory.
SPEAKER_01 (22:21):
Right.
SPEAKER_00 (22:21):
We have digital early detection tools, we have
new preventive drugs, we havestructured, evidence-based
lifestyle interventions.
It sounds like we solved thepuzzle.
SPEAKER_01 (22:30):
It sounds great on paper.
SPEAKER_00 (22:32):
Aaron Powell But when you take these pristine
scientific advancements and dropthem into the complex reality of
human society, human psychology,and the modern healthcare
system, you enter an absoluteminefield.
SPEAKER_01 (22:44):
The leaders at the spring twenty twenty-five
roundtable were acutely aware ofthis friction.
SPEAKER_00 (22:49):
Okay.
SPEAKER_01 (22:49):
A major focus of their meeting wasn't just the
biology, but the ethicalconsiderations around the
disclosure of these earlybiomarkers.
SPEAKER_00 (22:56):
That makes sense.
SPEAKER_01 (22:57):
Dr.
Trin steps back from the purescientific excitement and issues
a vital warning in the report.
What's the warning?
He says that while theadvancements are thrilling, this
is a moment for cautiousoptimism, not overstatement.
SPEAKER_00 (23:10):
Why the warning?
What is he worried about?
SPEAKER_01 (23:12):
He raises a barrage of incredibly difficult,
unanswered questions.
Who exactly should get theseearly biomarker blood tests?
How are the results interpretedacross different demographics?
How do we counsel patients whoreceive this predictive
information?
And crucially, how do we ensureequitable access to all of these
(23:32):
tools?
SPEAKER_00 (23:33):
If we connect this to the bigger picture, try to
imagine the immensepsychological burden of what we
are actually proposing here.
Let's role-play this scenario.
SPEAKER_01 (23:42):
Okay, let's do it.
SPEAKER_00 (23:43):
Think about what it really means for a doctor to sit
down with a perfectly healthy,high-functioning 50-year-old
person.
They are at the peak of theircareer, they are putting their
kids through college, they feelphysically and mentally
fantastic.
SPEAKER_01 (23:55):
Okay, fine.
Yeah.
SPEAKER_00 (23:56):
They took a blood test as part of a routine
physical, and the doctor says,Your results show you have the
specific biomarkers forAlzheimer's disease.
SPEAKER_01 (24:04):
You have essentially handed them a pre-diagnosis of a
devastating neurodegenerativedisease that might not manifest
behavioral symptoms for another10 or 15 years.
Wow.
The ethical dilemma is profound.
How does the medical systemcounsel that patient?
SPEAKER_00 (24:21):
Right.
SPEAKER_01 (24:21):
How do you deliver that news so they feel empowered
to take action, like joining aclinical trial or starting the
pointer protocol rather thanfeeling completely doomed,
depressed, and paralyzed byanxiety?
SPEAKER_00 (24:34):
It's a completely disruptive life event triggered
by a test for a disease theycannot even feel yet.
SPEAKER_01 (24:39):
Exactly.
SPEAKER_00 (24:40):
Will they change their retirement plans?
Will they look at everymisplaced set of car keys for
the next decade as the beginningof the end?
SPEAKER_01 (24:47):
Every time they forget a word, they'll panic.
SPEAKER_00 (24:49):
We are building the plane while we are flying it.
The biological science and thetechnology, the blood tests, the
digital assessments are movingat breakneck speed.
SPEAKER_01 (24:57):
Yes.
SPEAKER_00 (24:58):
But the social policy, the psychological
counseling frameworks, theinsurance structures, they are
lagging dangerously behind.
They really are.
We have the tools to see thestorm, but we don't have the
instruction manual for how todeploy that information safely
across a population of millions.
SPEAKER_01 (25:14):
That systemic infrastructural challenge is
exactly what Dr.
Peter Glevis highlights in thereport.
SPEAKER_00 (25:19):
Who's Dr.
Glebis?
SPEAKER_01 (25:21):
He is the chief of neurology at Marcus Neuroscience
Institute, and he brings a verypragmatic, macro-level view to
this paradigm shift.
Okay.
He argues that having the testsis not enough.
We urgently need to developstrict science-based guidelines
for this new era.
SPEAKER_00 (25:37):
Aaron Powell What kind of guidelines is he
demanding?
SPEAKER_01 (25:39):
He is prioritizing protocols on exactly who should
be screened, at what age theyshould be screened, and how the
screening and subsequentcounseling should be conducted.
SPEAKER_00 (25:49):
Which is critical, otherwise, you just have doctors
guessing how to handle it.
SPEAKER_01 (25:51):
Right.
Furthermore, he points out theharsh financial reality of
modern medicine.
SPEAKER_00 (25:56):
Uh, the money.
SPEAKER_01 (25:58):
Yes.
We need to ensure that insurancecoverage for these new
diagnostic methods is firmly inplace and that we have a
cost-effective way to identifyand treat these patients.
SPEAKER_00 (26:07):
Because if a specialized biomarker blood test
costs thousands of dollars outof pocket, and if only expensive
concierge medicine clinics offerthe structured, accountable
lifestyle coaching from thepointer trial, then we haven't
actually cured the Alzheimer'scrisis.
SPEAKER_01 (26:23):
No, we haven't.
SPEAKER_00 (26:24):
We've just created a dystopian scenario where wealthy
people get to save theirmemories and everyone else is
left in the reactive, tragicmodel of the past.
SPEAKER_01 (26:33):
That's a terrifying thought.
SPEAKER_00 (26:35):
Equity has to be the gravitational center of this
entire paradigm shift.
SPEAKER_01 (26:39):
Dr.
Glebis emphasizes that thesekinds of massive policy and
behavioral changes take time.
You cannot overhaul a globalmedical system and its deeply
entrenched insurance structuresovernight.
SPEAKER_00 (26:51):
It's like turning an aircraft carrier.
SPEAKER_01 (26:53):
Exactly.
He notes that sound science andeducation are the only ways to
support this massive societaltransition.
We have to methodically buildthe ethical and financial
infrastructure to support thescientific breakthroughs.
SPEAKER_00 (27:06):
So what does this all mean for you, the learner?
SPEAKER_01 (27:08):
It means education is the very first step in
building that infrastructure.
SPEAKER_00 (27:11):
Let's bring all of this together and recap the
mission we set out on today.
We explored how the globalmedical establishment is
actively executing a paradigmshift in Alzheimer's care.
SPEAKER_01 (27:21):
A huge one.
SPEAKER_00 (27:22):
Moving away from the tragic, reactive model of
waiting for severe cognitiveimpairment and transitioning
into a proactive, preventablemodel.
SPEAKER_01 (27:31):
We unpacked the new early warning toolkit, but we
also confronted the deep ethicaland systemic complexities of
this new frontier.
We explored the immensepsychological weight of a
pre-diagnosis.
SPEAKER_00 (27:44):
And the urgent need for systemic guidelines and
insurance coverage to ensurethat early detection leads to
equitable, accessible care foreveryone, not just a privileged
few.
SPEAKER_01 (27:53):
It is a brave, complex new world for brain
health.
SPEAKER_00 (27:56):
It really is.
But before we sign off, we wantto leave you with a final
thought to chew on.
Something that gets to the veryheart of how this science
intersects with your daily life.
SPEAKER_01 (28:06):
This raises an important question for all of us
as we look toward the future ofhealthcare.
If a simple digital assessmentor a routine blood test becomes
a standard, fully covered partof your yearly physical, just
like checking your bloodpressure or your cholesterol,
and it told you definitivelyyour brain's cognitive forecast
for a decade from now, how wouldthat knowledge change the way
(28:26):
you live your life tomorrow?
SPEAKER_00 (28:28):
Would a positive result paralyze you with fear
and anxiety?
SPEAKER_01 (28:32):
Or would it be the ultimate catalyst for change,
pushing you to instantlyrestructure your physical,
nutritional, and social habits?
SPEAKER_00 (28:39):
That is the incredibly personal question we
are all going to have to answerin the very near future.
Thank you so much for joining uson this deep dive.
SPEAKER_01 (28:47):
It's been great.
SPEAKER_00 (28:48):
Our goal is always to take these complex, paradigm
shifting ideas and make themaccessible, deeply engaging, and
practically relevant for you.
Keep asking the big questions,keep challenging the old models,
and most importantly, keeplearning.
We'll catch you on the next deepdive.
Imagine it is years, um, maybe even a full decade
before you ever forget a nameor, you know, misplace your
keys.
SPEAKER_01 (00:08):
Right.
Years before any of thosesubtle, kind of terrifying
moments of cognitive slip evencross your mind.
SPEAKER_00 (00:14):
Exactly.
You are, for all intents andpurposes, perfectly healthy.
Yeah.
I mean your memory is sharp, youare at the peak of your career,
and you're fully independent.
Yeah, just living your life.
But then you go into yourdoctor's office and a simple
blood test, or or perhaps adigital game you play on a
tablet in the waiting room.
SPEAKER_01 (00:31):
Like just tapping a screen while you wait.
SPEAKER_00 (00:33):
Yeah.
And that simple thing predictsthat you are already on the
biological path to Alzheimer'sdisease.
SPEAKER_01 (00:39):
Aaron Ross Powell I mean, it sounds like science
fiction, right?
But it is rapidly becoming ourclinical reality.
We are really sitting at theedge of a massive medical
frontier here.
SPEAKER_00 (00:49):
Welcome to the deep dive.
For you listening, whetheryou're, you know, prepping for a
healthcare meeting, trying tocatch up on the latest medical
trends, or you're just insanelycurious about human biology.
Our mission today is to get youfully up to speed on this
revolution.
SPEAKER_01 (01:02):
Aaron Powell Because it really is a revolution.
SPEAKER_00 (01:03):
Aaron Powell It is.
We are unpacking a fundamentalparadigm shift in how the
medical world approachesAlzheimer's disease.
I mean, we're talking about amonumental transition from a
reactive approach to a highlyproactive preventive one.
SPEAKER_01 (01:18):
Aaron Ross Powell What's fascinating here is the
sheer overwhelming scale of theissue we're dealing with.
We're pulling today from anincredibly comprehensive report
from March 2026, published inMedical News Today.
Right.
And it details the findings ofthe spring 2025 Alzheimer's
Association research roundtable.
That report points out that anestimated 32 million people
(01:41):
worldwide are currently livingwith Alzheimer's disease.
SPEAKER_00 (01:44):
32 million.
That is, I mean, that is thepopulation of a moderately sized
country.
SPEAKER_01 (01:48):
Exactly.
32 million.
And for decades, modern medicinehas essentially been fighting
this really complex, devastatingform of dementia with one arm
tied behind its back.
SPEAKER_00 (01:58):
Aaron Powell The global scale is staggering.
SPEAKER_01 (01:59):
Yeah.
SPEAKER_00 (02:00):
Because it's not just the 32 million lives.
Right.
SPEAKER_01 (02:03):
Not at all.
SPEAKER_00 (02:03):
It's the exponential number of caregivers and family
members whose lives arecompletely altered by it.
Trevor Burrus, Jr.
SPEAKER_01 (02:09):
The ripple effect is huge.
SPEAKER_00 (02:11):
Yeah.
So to understand it why thisshift from reaction to
prevention is such a massivedeal, we need to look at the
baseline of where we are comingfrom.
The spring 2025 Alzheimer'sAssociation research roundtable
wasn't just, you know, a casualsymposium.
SPEAKER_01 (02:25):
Right.
It was a major gathering.
Trevor Burrus, Jr.
SPEAKER_00 (02:27):
The report highlights that it brought
together leaders from academia,medical practice, the
pharmaceutical industry, andgovernment.
Trevor Burrus, Jr.
SPEAKER_01 (02:34):
You basically bring all those stakeholders into one
room when the entire foundationof a medical discipline needs to
be rebuilt.
SPEAKER_00 (02:40):
Exactly.
And the core shift theyoutlined, which was officially
published in Alzheimer's andDementia, translational research
and clinical interventions, ismoving from responding to
symptoms after they appear tofocusing intensely on risk
reduction and you know muchearlier treatment.
SPEAKER_01 (02:57):
Aaron Ross Powell Yeah.
Dr.
Suzanne E.
Schindler, she's the associateprofessor of neurology at
Washington University School ofMedicine in St.
Louis.
Okay.
She was the co-chair of thatroundtable session.
And she made an observation thattruly defines the historical
failure of our approach.
SPEAKER_00 (03:12):
Aaron Ross Powell What did she say?
SPEAKER_01 (03:13):
She pointed out that up until now, many patients with
Alzheimer's disease are onlydiagnosed after they have
already developed majorcognitive impairment and loss of
function.
SPEAKER_00 (03:22):
Okay, let's unpack this because major cognitive
impairment and loss of functionis incredibly sterile clinical
language.
SPEAKER_01 (03:29):
You know, it hides the reality.
SPEAKER_00 (03:31):
Right.
In the real world, for you oryour family, that means someone
is already struggling to managetheir daily finances, or they're
getting lost driving a familiarroute.
SPEAKER_01 (03:41):
Or they're failing to recognize a loved one.
SPEAKER_00 (03:43):
Which is just heartbreaking.
It means the biology has alreadywreaked havoc on the behavior.
SPEAKER_01 (03:48):
Dr.
Schindler really isolates thecore of why that late diagnosis
is so problematic.
She states that patients andtheir care partners are
typically receiving thisdiagnosis after the window when
interventions are most helpfuland patients can make truly
independent decisions.
Wow.
Yeah.
That last phrase is critical.
SPEAKER_00 (04:07):
Right.
The loss of independent decisionmaking.
SPEAKER_01 (04:09):
Exactly.
Because that fundamentallychanges the ethics and the
efficacy of medical care.
SPEAKER_00 (04:14):
That is heavy.
Because the loss of independentdecision making means the
disease has already taken thedriver's seat.
SPEAKER_01 (04:21):
It has.
SPEAKER_00 (04:22):
You might no longer have the cognitive capacity to
decide how you want your caremanaged, right?
Or or participate meaningfullyin planning your own financial
or medical future.
SPEAKER_01 (04:32):
Or even fully consent to participating in
clinical trials, which is a hugeissue.
SPEAKER_00 (04:38):
Wait, really?
The trials themselves areaffected.
SPEAKER_01 (04:41):
Oh, absolutely.
The clinical trials aspect is amassive hurdle in itself.
If a patient cannot consent, theburden falls to a proxy, like a
family member.
I see.
And that slows down research andadds layers of ethical
complexity.
We have historically been tryingto treat a disease at the exact
moment the patient loses theability to fight back.
SPEAKER_00 (05:01):
It sounds like we've historically been trying to
board up the windows after thehurricane has already torn the
roof off.
SPEAKER_01 (05:06):
That's exactly what it is.
SPEAKER_00 (05:07):
I mean, the storm has passed, the damage is
catastrophic, and we are showingup with plywood and nails
saying, All right, let's securethe house.
SPEAKER_01 (05:14):
Aaron Powell Right, a little too late.
SPEAKER_00 (05:15):
Aaron Ross Powell But with what we are seeing in
this report, it feels like we'refinally getting a weather radar.
We can see the storm forminghundreds of miles offshore.
Yes.
But I guess my question is, whyhas it taken so long to build
this radar?
Why have we been operating inthe dark for decades?
SPEAKER_01 (05:33):
Well, the primary hurdle has always been the
physical isolation of the brain.
SPEAKER_00 (05:37):
Okay.
SPEAKER_01 (05:38):
The biology of Alzheimer's involves the buildup
of specific proteins and thegradual destruction of neural
pathways.
Right.
But for decades, thosebiological changes were entirely
invisible to us in a livingpatient.
Aaron Ross Powell Wow.
SPEAKER_00 (05:51):
So we just couldn't see it happening.
SPEAKER_01 (05:52):
Aaron Ross Powell Right.
We simply did not have thetechnology to peer into a living
brain and detect the diseaseprocess before it manifested as
severe behavioral symptoms.
SPEAKER_00 (06:00):
Aaron Ross Powell So we had to rely entirely on
outward, late-stage behavioralcues to infer what was happening
biologically.
SPEAKER_01 (06:07):
Trevor Burrus Exactly.
We had to wait for the memoryloss to know the brain was under
attack.
SPEAKER_00 (06:11):
Aaron Ross Powell That's terrifying.
SPEAKER_01 (06:12):
Aaron Ross Powell It is.
And that's why Dr.
Schindler calls this atransformational time, precisely
because the invisible isbecoming visible.
SPEAKER_00 (06:19):
Aaron Ross Powell The window of intervention
hasn't just been nudged open, ithas been dramatically widened.
SPEAKER_01 (06:25):
Aaron Ross Powell Right.
We are shifting toward detectingand treating Alzheimer's before
that major cognitive impairmenthas occurred.
SPEAKER_00 (06:32):
Trevor Burrus Which is incredible.
And that transition frominvisible to visible brings us
perfectly to the new toolsmaking this weather radar
possible.
SPEAKER_01 (06:40):
Yes, the diagnostic toolkit.
SPEAKER_00 (06:42):
Because if you're going to track the biological
storm before it hits thebehavioral shore, we need highly
sophisticated equipment.
The source material lays out aspecific four-part diagnostic
toolkit for early stagedetection.
SPEAKER_01 (06:55):
Right.
It mentions biomarkers,specialized blood tests,
neuroimaging, and digitalcognitive assessment tools.
SPEAKER_00 (07:01):
So each of these represents a monumental leap
forward from the historicalstandard, right?
SPEAKER_01 (07:05):
Oh, huge.
Historically, a cognitiveassessment often involves simply
asking a patient to draw theface of a clock.
SPEAKER_00 (07:12):
Right, the clock drawing test.
SPEAKER_01 (07:13):
Yeah, or trying to get them to remember a sequence
of three words during an annualcheckup.
SPEAKER_00 (07:18):
Which seems so basic compared to what we have now.
I really want to zero in on twoof these new tools because the
underlying mechanisms arefascinating.
Digital cognitive assessmenttools and specialized blood
tests.
We read about computerizedcognitive assessments detecting
changes many years before majorimpairment.
How does a digital game spot adisease that, like a trained
(07:42):
neurologist talking to a patientin a room, might miss?
SPEAKER_01 (07:45):
Well, the difference lies in the sensitivity of
measurement.
SPEAKER_00 (07:49):
Okay.
SPEAKER_01 (07:49):
A traditional cognitive test is pretty binary.
You either remember the threewords or you don't.
SPEAKER_00 (07:54):
Right.
SPEAKER_01 (07:54):
But a sensitive digital cognitive assessment is
measuring microhesitations.
SPEAKER_00 (07:58):
Microhesitations.
SPEAKER_01 (07:59):
Yeah.
It is tracking incredibly subtleshifts in reaction time, pattern
recognition, and processingspeeds.
SPEAKER_00 (08:05):
Oh wow.
SPEAKER_01 (08:05):
It measures how your brain navigates complex,
multifaceted digital tasks downto the millisecond.
SPEAKER_00 (08:12):
The millisecond.
So it's way beyond humanperception.
SPEAKER_01 (08:14):
Exactly.
A human observer cannot catch a50-millisecond delay in
cognitive processing during anormal conversation, but an
algorithm can.
SPEAKER_00 (08:22):
That makes me think of a mechanic listening to a car
engine.
SPEAKER_01 (08:25):
Okay.
Yeah.
SPEAKER_00 (08:26):
You know, the check engine light hasn't come on yet,
and the car is still drivingdown the highway at 60 miles an
hour, just fine.
But the mechanic plugs in adiagnostic computer and it
detects a microscopic misfire inone cylinder.
SPEAKER_01 (08:38):
Right.
SPEAKER_00 (08:39):
The driver feels absolutely nothing, but the
machine knows the engine isstarting to fail.
SPEAKER_01 (08:44):
That is a highly accurate way to visualize it.
The digital assessment isfinding the absolute earliest
behavioral echoes of thebiological changes.
SPEAKER_00 (08:53):
That's incredible.
SPEAKER_01 (08:54):
And complementing that behavioral data are the
specialized blood tests.
SPEAKER_00 (08:58):
Let's talk about those.
SPEAKER_01 (09:00):
Dr.
Schindler explicitly confirmedthat these blood tests can
detect Alzheimer's-related brainchanges many years before the
cognitive impairment becomesapparent.
SPEAKER_00 (09:09):
Okay, stop there because we need to explain the
how of this.
SPEAKER_01 (09:12):
Sure.
SPEAKER_00 (09:13):
Because the brain is separated from the rest of the
body's bloodstream by the bloodbrain barrier, right?
Which acts like a biologicalfortress.
SPEAKER_01 (09:21):
Very true.
SPEAKER_00 (09:22):
So how on earth are we finding a brain disease in a
vial of blood drawn fromsomeone's arm?
SPEAKER_01 (09:27):
It's a great question.
The blood brain barrier ishighly selective, but it is not
entirely impermeable, especiallyover a lifetime.
SPEAKER_00 (09:35):
Okay.
SPEAKER_01 (09:36):
As the biological hallmarks of Alzheimer's begin
to develop as specific proteinsbegin to accumulate or misfold
in the brain, microscopic tracesof these proteins or the
biological byproducts of braincell stress inevitably cross
over into the peripheralbloodstream.
SPEAKER_00 (09:52):
Oh, I see.
SPEAKER_01 (09:53):
We call these biomarkers.
They are basically thebiological fingerprints of the
disease.
SPEAKER_00 (09:58):
So the disease leaves a trail, and the blood
test is like the magnifyingglass.
SPEAKER_01 (10:02):
Exactly.
Previously, the only way toaccurately detect these specific
biomarkers was through a highlyinvasive lumbar puncture to draw
cerebrospinal fluid.
Ouch.
Yeah.
Or through incredibly expensivespecialized neuroimaging like a
PEET scan.
SPEAKER_00 (10:18):
And you can't just give PET scans to everyone.
SPEAKER_01 (10:20):
Right.
Those are not screening toolsyou can deploy to the general
population.
They're too costly and complex.
SPEAKER_00 (10:25):
Makes sense.
SPEAKER_01 (10:26):
But the advancement of specialized blood tests means
we can now detect theseminuscule biomarker fingerprints
in a standard blood draw.
SPEAKER_00 (10:33):
Which you can get in a normal physical.
SPEAKER_01 (10:35):
Exactly.
SPEAKER_00 (10:35):
For you listening, especially if you actively avoid
medical information overload,here is the clear, undeniable
takeaway from this section ofour deep dive.
The timeline of Alzheimer'sdisease has been fundamentally
rewritten.
SPEAKER_01 (10:49):
Completely rewritten.
SPEAKER_00 (10:51):
The disease begins biologically long before it
begins behaviorally.
You can be biologically positivefor the early stages of
Alzheimer's while still beingbehaviorally perfect.
SPEAKER_01 (11:02):
Yes.
And separating the biology fromthe behavior is the exact wedge
that allows modern medicine tostep in.
Right.
Because if we can find thedisease early, if we can see the
biomarker fingerprints in ahealthy 50-year-old, the
immediate next question is whatdo we actually do with that
information?
SPEAKER_00 (11:20):
Right.
It's a great question.
Because if we have the weatherradar and we see the storm
coming a decade away, but wedon't have an evacuation plan or
way to disperse the clouds.
SPEAKER_01 (11:29):
Then we haven't helped the patient.
SPEAKER_00 (11:31):
Exactly.
We've just given them a decadeof severe anxiety.
SPEAKER_01 (11:33):
Which brings us to the pharmaceutical side of this
paradigm shift.
The report features insightsfrom Dr.
Christopher Weber.
SPEAKER_00 (11:40):
He's the director of global science initiatives at
the Alzheimer's Association,right?
SPEAKER_01 (11:44):
Yes, he is.
And he makes a point that servesas the foundation for this
entire proactive movement.
SPEAKER_00 (11:50):
What's his point?
SPEAKER_01 (11:50):
He says that early detection enables all proven
interventions to have theirabsolute greatest benefit.
SPEAKER_00 (11:56):
You want to put out the fire when it's just a spark
on the curtains, not when thewhole house is engulfed.
SPEAKER_01 (12:01):
Perfectly said.
And we actually have treatmentsto deploy at the spork stage
now.
SPEAKER_00 (12:06):
Wait, right now.
Today.
SPEAKER_01 (12:08):
Yes.
The article notes that medicinesdesigned to slow the early
stages of Alzheimer's havealready been approved in the
United States and in othercountries.
Wow.
SPEAKER_00 (12:16):
So we aren't just waiting on future miracles.
We have tools available today.
SPEAKER_01 (12:20):
We do.
But the report goes evenfurther, detailing ongoing
clinical trials that are pushingthe envelope to the absolute
edge of early intervention.
SPEAKER_00 (12:29):
Okay.
SPEAKER_01 (12:29):
It specifically highlights two major studies
Trailblazer Allstairs 3 andAHEAD 345.
SPEAKER_00 (12:36):
The patient criteria for these trials is what makes
them so revolutionary, isn't it?
SPEAKER_01 (12:40):
Oh, absolutely.
They are testing these new drugson people who show early
biological signs in the brain,those biomarkers we just talked
about, but who do not yet haveany memory issues.
SPEAKER_00 (12:52):
That is wild.
They are giving Alzheimer'smedication to people who have
perfect functioning memories.
SPEAKER_01 (12:58):
Yes.
SPEAKER_00 (12:58):
So what is the mechanism of action here?
What are these drugs actuallydoing inside a healthy seeming
brain?
SPEAKER_01 (13:04):
Aaron Ross Powell Well, while the report doesn't
dive into the deep molecularchemistry, the conceptual
mechanism is about clearing thebiological debris.
SPEAKER_00 (13:12):
Okay, clearing debris.
SPEAKER_01 (13:14):
Yeah.
If the blood tests show that theproblematic proteins associated
with Alzheimer's are justbeginning to accumulate in the
brain, these trials are testingwhether introducing a drug now
can clear those proteins.
SPEAKER_00 (13:25):
Before they do damage.
SPEAKER_01 (13:26):
Exactly.
Clear them or halt theiraccumulation before they cause
enough cellular damage totrigger memory loss.
SPEAKER_00 (13:32):
That is incredible.
SPEAKER_01 (13:33):
Dr.
Weber offers a brilliantcomparison that really
demystifies this whole approach.
He likens this new strategy tohow doctors treat heart disease.
SPEAKER_00 (13:42):
Oh, I like that.
Think about heart disease.
We don't wait for the patient tobe clutching their chest in the
emergency room, having amassive, irreversible myocardial
infarction.
SPEAKER_01 (13:53):
No, we don't.
SPEAKER_00 (13:54):
We test their cholesterol when they're 40
years old.
If their lipid biomarkers arehigh, we prescribe a statin.
SPEAKER_01 (14:00):
Right.
We treat the biological riskfactor, the high cholesterol,
decades before the catastrophicbehavioral event, the heart
attack.
SPEAKER_00 (14:07):
And Dr.
Weber is suggesting we arefinally applying this exact same
preventive, proactive model tothe brain.
SPEAKER_01 (14:14):
That's it exactly.
We find the biological riskfactor, the early signs of
Alzheimer's pathology via bloodtests or digital assessments,
and we treat it biologicallybefore the memory degrades.
SPEAKER_00 (14:25):
Here's where it gets really interesting, though.
We can talk about biomarkers,lipid panels, and trials like
Trailblazer all day, but Dr.
Weber grounds this in a deeplyhuman reality.
SPEAKER_01 (14:35):
He really does.
SPEAKER_00 (14:36):
He told Medical News today giving people more time
without memory and thinkingchanges.
That's something everybodywants.
SPEAKER_01 (14:42):
It is the ultimate metric of success.
Not just clearing proteins, butpreserving humanity.
SPEAKER_00 (14:47):
Yes.
Because it is so easy to getlost in the clinical data of a
medical report, you know.
But this isn't just about movingstatistical numbers on a chart.
SPEAKER_01 (14:56):
No, not at all.
SPEAKER_00 (14:57):
Buying time is everything.
It's about preserving a person'sidentity, it's about preserving
their relationships, theirability to drive to the grocery
store, their ability to live intheir own home.
SPEAKER_01 (15:07):
Independence.
SPEAKER_00 (15:08):
Exactly.
If a preventative drug can givea grandfather five more years of
knowing his grandchildren'snames, that is an immeasurable
victory for that family.
SPEAKER_01 (15:19):
It is the definition of a medical breakthrough.
SPEAKER_00 (15:22):
It really is.
SPEAKER_01 (15:22):
However, the report clearly outlines that
pharmaceutical interventions arenot the only tools we have.
In fact, relying solely on apill ignores the behavioral and
environmental side of theequation entirely.
SPEAKER_00 (15:33):
Right, because there's more to health than just
taking a pill.
SPEAKER_01 (15:36):
Furthermore, for a huge portion of the global
population, these advanced drugsmight not be an option.
SPEAKER_00 (15:41):
Why not?
SPEAKER_01 (15:42):
Well, due to costs, geographical access, or
compounding medical conditions,some people just can't take
them.
SPEAKER_00 (15:48):
So if these new drugs are only for people who
can afford them or tolerate theside effects, what happens to
the millions of people who get apositive blood test but can't
take the pill?
SPEAKER_01 (15:59):
That's a huge concern.
SPEAKER_00 (16:01):
Because we can't just leave them hanging in the
reactive model, right?
Which brings us to the lifestylecomponent.
The Alzheimer's Associationisn't just focused on
pharmaceuticals, the round tableheavily emphasized early
lifestyle interventions.
SPEAKER_01 (16:15):
Yes.
And they specifically pointed tofindings from the U.S.
Pointer trial.
SPEAKER_00 (16:19):
Okay, tell me about the Pointer trial.
SPEAKER_01 (16:21):
Aaron Powell The U.S.
Pointer trial is fascinatingbecause it elevates lifestyle
modification from generic adviceto clinical intervention.
I see.
It identified four distinctpillars of intervention that
provided the most benefit forolder adults who were at high
risk of developing Alzheimer's.
SPEAKER_00 (16:37):
What are the four pillars?
SPEAKER_01 (16:38):
They are.
Physical activity, nutrition,social and cognitive challenges,
and health coaching.
SPEAKER_00 (16:44):
Okay.
I have to play the skeptic herefor a moment.
Go for it.
Because as a listener, you heareat right and exercise for
literally every disease underthe sun.
SPEAKER_01 (16:52):
It's sure it's a cliche at this point.
SPEAKER_00 (16:54):
Aaron Ross Powell It's the generic catch-all
advice for heart disease,diabetes, joint pain, bad sleep.
Are we really saying that eatinga side salad and doing a Sunday
crossword puzzle can actuallystop a biological juggernaut
like Alzheimer's disease?
SPEAKER_01 (17:09):
Oh man, if it were just a casual salad and a
crossword puzzle, you would beabsolutely right to be
skeptical.
Right.
But Dr.
Weber's specific phrasing in thereport is the key.
He states that research showshealthy habits with structure
and accountability can improvethinking and support brain
health.
SPEAKER_00 (17:26):
Okay.
Structure and accountability.
SPEAKER_01 (17:28):
There is a massive clinical difference between
occasionally deciding to take awalk versus a structured
medically accountableintervention program.
SPEAKER_00 (17:37):
Explain the difference.
How does structure actuallychange the outcome for the
brain?
SPEAKER_01 (17:40):
Let's break down the four pillars of the pointer
trial conceptually.
Physical activity isn't justmoving around, it's a targeted
cardiovascular regimen designedto increase blood flow and
oxygenate the brain, whichpotentially stimulates the
growth of new neuralconnections.
Nutrition isn't just eating lesssugar, it's a specific
prescribed overhaul designed toreduce systemic inflammation.
SPEAKER_00 (18:02):
And inflammation's a big deal.
SPEAKER_01 (18:04):
Massive.
We know systemic inflammation isa driver of neurodegenerative
disease.
SPEAKER_00 (18:08):
Got it.
What about the cognitive side?
SPEAKER_01 (18:11):
Social and cognitive challenges aren't passive games,
they are rigorous engagementsthat force the brain to process
unpredictable, real-timeinformation.
SPEAKER_00 (18:20):
Oh, like socializing.
SPEAKER_01 (18:22):
Yes.
Socializing requires readingfacial expressions, recalling
past conversations, andformulating responses.
SPEAKER_00 (18:29):
That's true.
SPEAKER_01 (18:29):
It is actually one of the most cognitively
demanding tasks a human canperform.
SPEAKER_00 (18:33):
That makes perfect sense.
Social interaction is areal-time stress test for the
brain's processing speed andmemory retrieval.
A crossword puzzle doesn't talkback or change the subject
unpredictably.
SPEAKER_01 (18:44):
Exactly.
And tying all of this togetheris the fourth pillar health
coaching.
SPEAKER_00 (18:49):
The accountability part.
SPEAKER_01 (18:50):
Right.
The coaching provides thestructure and accountability.
It ensures compliance, tracksprogress, and adjusts the
interventions based on thepatient's biological response.
Wow.
It is prescribed lifestylemodification, treated with the
exact same rigor and seriousnessas a pharmaceutical
prescription.
SPEAKER_00 (19:08):
It's the difference between doing some half-hearted
stretches in your living roomand going to a prescribed
redirected physical therapyprogram after a knee
replacement.
SPEAKER_01 (19:18):
Perfect analogy.
SPEAKER_00 (19:19):
The structure and the oversight are what drive the
physical adaptation.
SPEAKER_01 (19:23):
Dr.
Dung Trin, an internist andchief medical officer of the
Healthy Brain Clinic, providescrucial perspective on this in
the report.
SPEAKER_00 (19:30):
What does he say?
SPEAKER_01 (19:31):
He makes a statement that frames this entire
approach.
He says lifestyle changes shouldbe seen as foundational, not
optional.
SPEAKER_00 (19:38):
Foundational, not optional.
I love that.
SPEAKER_01 (19:40):
And he breaks down the utility of these structured
lifestyle measures into threedistinct practical roles in
clinical medicine.
SPEAKER_00 (19:47):
Let's walk through Dr.
Trin's three roles because thisis where the theory hits the
pavement.
SPEAKER_01 (19:52):
Okay, first, he points out that lifestyle
interventions are broadlyapplicable.
SPEAKER_00 (19:56):
Right.
SPEAKER_01 (19:56):
As we discussed, not everyone is going to be a
candidate for early stageAlzheimer's drugs, but almost
everyone, regardless of theirmedical background or financial
status, can safely engage insome form of structured physical
activity, nutritionalimprovement, and cognitive
challenge.
SPEAKER_00 (20:13):
Right.
It is an incredibly accessibletool.
You don't need a million-dollarlab to go for a vigorous walk or
have a deep conversation.
Exactly.
So if role one is accessibility,I imagine rule two is that it
stacks with the medication.
SPEAKER_01 (20:26):
You've hit the nail on the head.
SPEAKER_00 (20:27):
You aren't choosing between a pill and a diet,
you're attacking the diseasefrom multiple angles.
SPEAKER_01 (20:32):
Dr.
Trin notes that lifestylechanges complement medical
treatment.
They do not compete with it.
SPEAKER_00 (20:37):
That's great.
SPEAKER_01 (20:38):
If a patient is a candidate for the new
pharmaceuticals like those inthe trailblazer or a head
trials, adopting the fourpillars of the pointer trial
will only support that medicalintervention.
SPEAKER_00 (20:49):
You are clearing the biological debris with the drug
while simultaneously reducinginflammation and strengthening
neural pathways throughlifestyle.
SPEAKER_01 (20:59):
It is a comprehensive, two-pronged
attack.
SPEAKER_00 (21:02):
That makes total sense.
And the third role.
The third role is perhaps themost psychologically significant
for the patient.
SPEAKER_01 (21:08):
Okay.
SPEAKER_00 (21:09):
Dr.
Trin emphasizes that lifestylemeasures shift the conversation
from fear to empowerment.
SPEAKER_01 (21:16):
I want to highlight this for you listening because
this is the ultimatepsychological takeaway.
SPEAKER_00 (21:20):
It really is.
SPEAKER_01 (21:21):
Think about the historical Alzheimer's diagnosis
we talked about at thebeginning.
It was a death sentence for yourmemory, delivered when it was
too late to do anything,resulting in absolute fear and
helplessness.
But Dr.
Trent is pointing out thatbecause we can detect risk
earlier, patients can beginworking on their brain health
right away through thesestructured lifestyle changes.
SPEAKER_00 (21:42):
Yes, even while they are undergoing further medical
evaluation or are waiting fortrial approval.
SPEAKER_01 (21:48):
You don't have to sit in a waiting room paralyzed
by fear.
The power is back in your handsthe moment you leave the clinic.
It's a profound psychologicalshift.
But as we move from the clinicalideal of Empowerment to the
messy reality of the healthcaresystem, things get complicated.
Giving people this powerfulpredictive information years in
(22:08):
advance opens up an entirelynew, highly complex set of
problems.
SPEAKER_00 (22:14):
We absolutely have to address the fallout.
Up to this point, we've beenpainting a picture of total
scientific victory.
SPEAKER_01 (22:21):
Right.
SPEAKER_00 (22:21):
We have digital early detection tools, we have
new preventive drugs, we havestructured, evidence-based
lifestyle interventions.
It sounds like we solved thepuzzle.
SPEAKER_01 (22:30):
It sounds great on paper.
SPEAKER_00 (22:32):
Aaron Powell But when you take these pristine
scientific advancements and dropthem into the complex reality of
human society, human psychology,and the modern healthcare
system, you enter an absoluteminefield.
SPEAKER_01 (22:44):
The leaders at the spring twenty twenty-five
roundtable were acutely aware ofthis friction.
SPEAKER_00 (22:49):
Okay.
SPEAKER_01 (22:49):
A major focus of their meeting wasn't just the
biology, but the ethicalconsiderations around the
disclosure of these earlybiomarkers.
SPEAKER_00 (22:56):
That makes sense.
SPEAKER_01 (22:57):
Dr.
Trin steps back from the purescientific excitement and issues
a vital warning in the report.
What's the warning?
He says that while theadvancements are thrilling, this
is a moment for cautiousoptimism, not overstatement.
SPEAKER_00 (23:10):
Why the warning?
What is he worried about?
SPEAKER_01 (23:12):
He raises a barrage of incredibly difficult,
unanswered questions.
Who exactly should get theseearly biomarker blood tests?
How are the results interpretedacross different demographics?
How do we counsel patients whoreceive this predictive
information?
And crucially, how do we ensureequitable access to all of these
(23:32):
tools?
SPEAKER_00 (23:33):
If we connect this to the bigger picture, try to
imagine the immensepsychological burden of what we
are actually proposing here.
Let's role-play this scenario.
SPEAKER_01 (23:42):
Okay, let's do it.
SPEAKER_00 (23:43):
Think about what it really means for a doctor to sit
down with a perfectly healthy,high-functioning 50-year-old
person.
They are at the peak of theircareer, they are putting their
kids through college, they feelphysically and mentally
fantastic.
SPEAKER_01 (23:55):
Okay, fine.
Yeah.
SPEAKER_00 (23:56):
They took a blood test as part of a routine
physical, and the doctor says,Your results show you have the
specific biomarkers forAlzheimer's disease.
SPEAKER_01 (24:04):
You have essentially handed them a pre-diagnosis of a
devastating neurodegenerativedisease that might not manifest
behavioral symptoms for another10 or 15 years.
Wow.
The ethical dilemma is profound.
How does the medical systemcounsel that patient?
SPEAKER_00 (24:21):
Right.
SPEAKER_01 (24:21):
How do you deliver that news so they feel empowered
to take action, like joining aclinical trial or starting the
pointer protocol rather thanfeeling completely doomed,
depressed, and paralyzed byanxiety?
SPEAKER_00 (24:34):
It's a completely disruptive life event triggered
by a test for a disease theycannot even feel yet.
SPEAKER_01 (24:39):
Exactly.
SPEAKER_00 (24:40):
Will they change their retirement plans?
Will they look at everymisplaced set of car keys for
the next decade as the beginningof the end?
SPEAKER_01 (24:47):
Every time they forget a word, they'll panic.
SPEAKER_00 (24:49):
We are building the plane while we are flying it.
The biological science and thetechnology, the blood tests, the
digital assessments are movingat breakneck speed.
SPEAKER_01 (24:57):
Yes.
SPEAKER_00 (24:58):
But the social policy, the psychological
counseling frameworks, theinsurance structures, they are
lagging dangerously behind.
They really are.
We have the tools to see thestorm, but we don't have the
instruction manual for how todeploy that information safely
across a population of millions.
SPEAKER_01 (25:14):
That systemic infrastructural challenge is
exactly what Dr.
Peter Glevis highlights in thereport.
SPEAKER_00 (25:19):
Who's Dr.
Glebis?
SPEAKER_01 (25:21):
He is the chief of neurology at Marcus Neuroscience
Institute, and he brings a verypragmatic, macro-level view to
this paradigm shift.
Okay.
He argues that having the testsis not enough.
We urgently need to developstrict science-based guidelines
for this new era.
SPEAKER_00 (25:37):
Aaron Powell What kind of guidelines is he
demanding?
SPEAKER_01 (25:39):
He is prioritizing protocols on exactly who should
be screened, at what age theyshould be screened, and how the
screening and subsequentcounseling should be conducted.
SPEAKER_00 (25:49):
Which is critical, otherwise, you just have doctors
guessing how to handle it.
SPEAKER_01 (25:51):
Right.
Furthermore, he points out theharsh financial reality of
modern medicine.
SPEAKER_00 (25:56):
Uh, the money.
SPEAKER_01 (25:58):
Yes.
We need to ensure that insurancecoverage for these new
diagnostic methods is firmly inplace and that we have a
cost-effective way to identifyand treat these patients.
SPEAKER_00 (26:07):
Because if a specialized biomarker blood test
costs thousands of dollars outof pocket, and if only expensive
concierge medicine clinics offerthe structured, accountable
lifestyle coaching from thepointer trial, then we haven't
actually cured the Alzheimer'scrisis.
SPEAKER_01 (26:23):
No, we haven't.
SPEAKER_00 (26:24):
We've just created a dystopian scenario where wealthy
people get to save theirmemories and everyone else is
left in the reactive, tragicmodel of the past.
SPEAKER_01 (26:33):
That's a terrifying thought.
SPEAKER_00 (26:35):
Equity has to be the gravitational center of this
entire paradigm shift.
SPEAKER_01 (26:39):
Dr.
Glebis emphasizes that thesekinds of massive policy and
behavioral changes take time.
You cannot overhaul a globalmedical system and its deeply
entrenched insurance structuresovernight.
SPEAKER_00 (26:51):
It's like turning an aircraft carrier.
SPEAKER_01 (26:53):
Exactly.
He notes that sound science andeducation are the only ways to
support this massive societaltransition.
We have to methodically buildthe ethical and financial
infrastructure to support thescientific breakthroughs.
SPEAKER_00 (27:06):
So what does this all mean for you, the learner?
SPEAKER_01 (27:08):
It means education is the very first step in
building that infrastructure.
SPEAKER_00 (27:11):
Let's bring all of this together and recap the
mission we set out on today.
We explored how the globalmedical establishment is
actively executing a paradigmshift in Alzheimer's care.
SPEAKER_01 (27:21):
A huge one.
SPEAKER_00 (27:22):
Moving away from the tragic, reactive model of
waiting for severe cognitiveimpairment and transitioning
into a proactive, preventablemodel.
SPEAKER_01 (27:31):
We unpacked the new early warning toolkit, but we
also confronted the deep ethicaland systemic complexities of
this new frontier.
We explored the immensepsychological weight of a
pre-diagnosis.
SPEAKER_00 (27:44):
And the urgent need for systemic guidelines and
insurance coverage to ensurethat early detection leads to
equitable, accessible care foreveryone, not just a privileged
few.
SPEAKER_01 (27:53):
It is a brave, complex new world for brain
health.
SPEAKER_00 (27:56):
It really is.
But before we sign off, we wantto leave you with a final
thought to chew on.
Something that gets to the veryheart of how this science
intersects with your daily life.
SPEAKER_01 (28:06):
This raises an important question for all of us
as we look toward the future ofhealthcare.
If a simple digital assessmentor a routine blood test becomes
a standard, fully covered partof your yearly physical, just
like checking your bloodpressure or your cholesterol,
and it told you definitivelyyour brain's cognitive forecast
for a decade from now, how wouldthat knowledge change the way
(28:26):
you live your life tomorrow?
SPEAKER_00 (28:28):
Would a positive result paralyze you with fear
and anxiety?
SPEAKER_01 (28:32):
Or would it be the ultimate catalyst for change,
pushing you to instantlyrestructure your physical,
nutritional, and social habits?
SPEAKER_00 (28:39):
That is the incredibly personal question we
are all going to have to answerin the very near future.
Thank you so much for joining uson this deep dive.
SPEAKER_01 (28:47):
It's been great.
SPEAKER_00 (28:48):
Our goal is always to take these complex, paradigm
shifting ideas and make themaccessible, deeply engaging, and
practically relevant for you.
Keep asking the big questions,keep challenging the old models,
and most importantly, keeplearning.
We'll catch you on the next deepdive.
Popular Podcasts
Joy 101 with Hoda Kotb
Joy is essential. And it's also elusive. You can't order it, borrow it, or simply hope it into life. But now, there's a new and exciting way to start your journey toward a more joyful existence: The Joy 101 Podcast with Hoda! Best known for her Emmy-winning work and co-anchoring Today, Hoda Kotb infuses her authenticity, curiosity, and warmth into conversations with the world’s most fascinating people. Entertainment legends, sport icons, wellness experts, and everyday folks will share how they find, allow, and experience joy. Hoda will offer her own tips and takes on seeking a more balanced, harmonious life. If you're craving inspiration, support, and useful tools to maximize your joy, tune in to these candid, uplifting, and moving on-air chats. Joy after a breakup, joy as an empty-nester, joy after loss, joy as a caretaker — Hoda's new podcast will speak to you. Joy 101 with Hoda Kotb, an iHeartPodcast.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com